AJ1-11095 is a first-in-class Type II JAK2 inhibitor currently in a Phase 1 study for the treatment of patients with ...

Shares are up 7% in trading today, after Geron announced a strategic restructuring to "position the company for long-term ...

Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with ...

Beyond blood cancers, GT Biopharma is developing GTB-5550, which targets B7H3, a protein commonly found across various solid tumor types including breast, lung, ovarian, pancreatic, bladder, and ...

Myelofibrosis Market Include Novartis, AstraZeneca, Cellenkos, Jacobio Pharmaceuticals, Ohmoncology, Geron Corporation, Incyte Corporation, Keros Therapeutics ...

Data were shared at the 67th Annual Meeting of the American Society of Hematology (ASH) ORLANDO, Fla.--(BUSINESS WIRE)--December 8, 2025-- Opna Bio, ...

Incyte ( INCY) on Sunday said the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ...

Onctura initiates phase I/II trial of roginolisib in patients with myelofibrosis who are no longer responding to JAK inhibition: Geneva, Switzerland Friday, December 5, 2025, 15: ...

The Phase II OCULE-01 study in uveal melanoma started in March 2025, the PULMO-01 study in non-small cell lung cancer (NSCLC) started in May 2025 and the HEMA-MED Phase I/II study in myelofibrosis ...

Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced positive new data from its pipeline of allogeneic ...

Graft-versus-host disease (GVHD) is a potential post-transplant complication. Here’s how one patient and his wife are ...

Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today announced positive results from ...